Related Experiment Videos
[Chemotherapy using cisplatin in bone and soft tissue sarcoma]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1987
Summary
Cisplatin shows efficacy in bone and soft tissue sarcomas, with manageable side effects like vomiting and hearing loss. It is a viable option for advanced or resistant cancers, but requires careful use in adjuvant chemotherapy.
Area of Science:
- Oncology
- Pharmacology
Context:
- Bone and soft tissue sarcomas are challenging malignancies.
- Cisplatin is a platinum-based chemotherapy agent with known toxicities.
Purpose:
- To evaluate the efficacy and toxicity of cisplatin in patients with bone and soft tissue sarcomas.
- To determine cisplatin's role in metastatic and adjuvant settings.
Summary:
- Cisplatin treatment in 14 sarcoma patients resulted in severe but short-lived vomiting and dose-dependent renal dysfunction. High-frequency hearing loss occurred in some patients without conversational impact.
- Partial or minor responses were observed in metastatic osteosarcomas, while soft tissue sarcomas showed no response.
- Three osteosarcoma patients receiving adjuvant cisplatin remained disease-free for extended periods post-surgery.
Impact:
- Cisplatin is a potential first-line agent for adriamycin- or methotrexate-resistant sarcomas.
- Potential challenges exist for cisplatin's use in adjuvant chemotherapy due to its side effect profile.